| 产品名称 | Quartett C-T004/P-T004 | pan-TRK (QR008) |
|---|---|
| 目录号 | C-T004/P-T004 |
| 别名 | pan-TRK |
| 外观 | 见COA |
| 分子量 | |
| CAS | |
| 溶解度 | |
| 存储条件 | 见COA |
| 保存时间 | 见COA |
| 备注1 | |
| 备注2 |
Quartett C-C031/P-C031 | CD31 (QR034)
品名：pan-TRK (QR008) | Recombinant monoclonal rabbit antibody
货号：C-T004/P-T004
品牌：Quartett
规格：0.1 ml; 0.5 ml; 1 ml; 3 ml; 7 ml; 15 ml
产品描述
| Application | IHC (FFPE) | Host | Rabbit |
| Subclass | IgG | Dilution range | 1:50 – 1:200 |
| Cellular localization | Cytoplasm, membrane, nucleus | Control | Cerebellum, appendix |
| Immunogen | Synthetic peptide from human pan-TRK | ||
Anti-pan-TRK (clone QR008) is a sensitive and specific marker for the detection of NTRK fusion tumors. The neurotrophic tyrosine kinase receptor (NTRK or TRK) family represents a subset of transmembrane tyrosine kinases responsible for neuronal development. The members of this receptor family are TRKA, TRKB, and TRKC, and they are encoded by the NTRK1, NTRK2, and NTRK3 genes. NTRK fusions can trigger carcinogenesis in both neurogenic and non-neurogenic cells. Fusions with a variety of gene partners are oncogenic drivers in various tumor types. NTRK fusions are characteristic of some rare cancers such as secretory carcinoma of the breast or salivary gland and infantile fibrosarcoma, but also of some common cancers such as melanoma, glioma, and thyroid, lung, and colon carcinoma. Several TRK inhibitors have been recently developed and have shown good response rates in neoplasms with NTRK gene fusions; therefore, the identification of these fusions is an essential tool for assessing treatment options for certain oncological diseases. The specific staining patterns vary depending on the fusion partner and appear to correlate with the subcellular localization of the fusion partners. Tumors with NTRK1/2 fusions showed cytoplasmic expression; perinuclear and nuclear membrane staining have been reported rarely. Tumors with NTRK3 fusions showed cytoplasmic or nuclear expression.
